Mitsubishi UFJ Trust & Banking Corp Invests $14.45 Million in Insmed, Inc. $INSM

Mitsubishi UFJ Trust & Banking Corp purchased a new position in shares of Insmed, Inc. (NASDAQ:INSM) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 83,032 shares of the biopharmaceutical company’s stock, valued at approximately $14,451,000.

Several other institutional investors have also modified their holdings of the stock. CIBC Private Wealth Group LLC raised its holdings in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares during the period. Kingsview Wealth Management LLC raised its holdings in shares of Insmed by 2.7% during the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 60 shares during the period. Choreo LLC grew its position in Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 65 shares during the period. ORG Partners LLC grew its position in Insmed by 12.7% in the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 74 shares during the period. Finally, Spire Wealth Management grew its position in Insmed by 11.5% in the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 80 shares during the period.

Insider Activity at Insmed

In related news, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. This trade represents a 45.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO William Lewis sold 13,396 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84. Following the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at $44,512,131.15. This trade represents a 4.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 179,777 shares of company stock worth $28,252,720 in the last three months. 2.10% of the stock is owned by company insiders.

Insmed Price Performance

Insmed stock opened at $136.33 on Friday. The company’s 50 day simple moving average is $147.89 and its 200-day simple moving average is $166.19. The company has a market capitalization of $29.43 billion, a price-to-earnings ratio of -21.27 and a beta of 1.10. Insmed, Inc. has a 1 year low of $63.81 and a 1 year high of $212.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. During the same period last year, the firm posted ($1.32) earnings per share. Insmed’s revenue was up 152.6% on a year-over-year basis. As a group, equities research analysts expect that Insmed, Inc. will post -2.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on INSM shares. UBS Group lowered their price objective on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 6th. Barclays increased their price objective on Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Royal Bank Of Canada increased their price objective on Insmed from $212.00 to $216.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Finally, Stifel Nicolaus increased their price objective on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $213.23.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.